No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Friedreich Ataxia (FA) is a rare, inherited, progressive neurodegenerative disorder that affects the nervous system. It is caused by a mutation in the FXN gene, which leads to a deficiency of the frataxin protein. As a result, patients experience a wide range of symptoms, including ataxia, muscle weakness, and sensory loss.
The Friedreich Ataxia Drug market is a subset of the Central Nervous System Drugs market. It is composed of drugs that are used to treat the symptoms of FA, such as ataxia, muscle weakness, and sensory loss. These drugs are typically administered orally or intravenously, and may include anticonvulsants, muscle relaxants, and other medications.
Some companies in the Friedreich Ataxia Drug market include Biogen, Sanofi, and Novartis. These companies are involved in the development and manufacture of drugs for the treatment of FA. Additionally, there are several smaller companies that are involved in the research and development of new drugs for the treatment of FA. Show Less Read more
